GLUE

Quote

Short

News

Articles

Message Board

Monte Rosa Therapeutics Inc. (NASDAQ : GLUE ) News

Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) News Releases

GLUE News Releases

May 07, 2026 07:34:05 am

SeekingAlpha

Monte Rosa Therapeutics reports Q1 results

May 07, 2026 07:00:00 am

GlobeNewswire

Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 05, 2026 04:01:00 pm

GlobeNewswire

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 21, 2026 01:53:49 pm

Motley Fool

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

April 20, 2026 07:00:00 am

GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

March 17, 2026 07:00:00 am

GlobeNewswire

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

March 16, 2026 07:26:05 am

SeekingAlpha

Monte Rosa rises on J&J collaboration for cancer therapy trial

March 16, 2026 07:00:00 am

GlobeNewswire

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

February 24, 2026 07:00:00 am

GlobeNewswire

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

January 14, 2026 07:05:26 am

KlickAnalytics

GLUE Price Target Alert: $37.00. Issued by Piper Sandler

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account